Efficacy of a new topical cyclosporine A formulation in the treatment of atopic dermatitis in dogs

Veterinary Journal

Volumn 197, Issue 2, 2013, Pages 280-285

  Puigdemont, Anna ^a   Brazís, Pilar ^b   Ordeix, Laura ^b,c   Dalmau, Annabel ^d   Fuertes, Esther ^e   Olivar, Ana ^f   Pérez, Christian ^g   Ravera, Iván ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVET   (Spain)

^c Hospital Ars Veterinaria   (Spain)

^d Mediterrani Veterinaris   (Spain)

^e Primary Care Centre Poble Sec   (Spain)

^f Hospital Veterinario Dr Palacios   (Spain)

^g NONE   (Spain)

Author keywords

Atopic dermatitis; Clinical trial; Cyclosporine; Dog; Topical

Indexed keywords

CYCLOSPORIN A; PLACEBO;

ADVERSE OUTCOME; ARTICLE; ATOPIC DERMATITIS; BICIPITAL TENDONITIS; CONTROLLED STUDY; DISEASE SEVERITY; DOG DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; MALE; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; PARALLEL DESIGN; PILOT STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TENDINITIS; VERRUCA VULGARIS; VISUAL ANALOG SCALE; VOMITING;

ATOPIC DERMATITIS; CLINICAL TRIAL; CYCLOSPORINE; DOG; TOPICAL;

ADMINISTRATION, TOPICAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DERMATITIS, ATOPIC; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FEMALE; MALE;

ANIMALIA; CANIS FAMILIARIS;

EID: 84881660143     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2013.02.018     Document Type: Article

References (33)

1. Amon E.U. Cyclosporin A inhibits histamine release from human peripheral basophils and human skin mast cells. Inflammation Research 1992, 36:C250-C252.
2. Amor K.T., Ryan C., Menter A. The use of cyclosporine in dermatology: Part I. Journal of the American Academy of Dermatology 2010, 63:925-946.
3. Bensignor E. Canine atopic dermatitis. Bulletin de l'Académie Nationale de Médicine 2010, 194:1357-1364.
4. Bussmann C., Bieber T., Novak N. Systemic therapeutic options for severe atopic dermatitis. Journal der Deutschen Dermatologischen Gesellschaft 2009, 7:205-219.
5. Deboer D.J., Schafer J.H., Salsbury C.S., Blum J.R., Beale K.M., Vitale C.B., Muse R., Moriello K.A., Garfield R.A., Keefe T.J., McArthur T.R. Multiple-center study of recuded-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus. American Journal of Veterinary Research 2002, 63:408-413.
6. Diesel A., Moriello K.A. A busy clinician's review of cyclosporine. Veterinary Medicine 2008, 103:266-268.
7. Ferraccioli G.F., Tomietto P., De Santis M. Rationale for T cell inhibition by cyclosporine A in major autoimmune diseases. Annals of the New York Academy of Sciences 2005, 1051:658-665.
8. García G., Ferrer L., De Mora F., Puigdemont A. Inhibition of histamine release from dispersed canine skin mast cells. Veterinary Dermatology 1998, 9:81-86.
9. Giese T., Zeier M., Schemmer P., Uhl W., Schoels M., Dengler T., Buechler M., Meuer S. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: A novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004, 77:339-344.
10. Gottlieb S.L., Heftler N.S., Gilleaudeau P., Johnson R., Vallat V.P., Wolfe J., Gottlieb A.B., Krueger J.G. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: A clinical and pathologic study. Journal of the American Academy of Dermatology 1995, 33:637-645.
11. Gupta A.K., Baadsgaard O., Ellis C.N., Voorhees J.J., Cooper K.D. Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporine A. Archives of Dermatological Research 1989, 281:219-226.
12. Heinrich N.A., McKeever P.J., Eisenschenk M.C. Adverse events in 50 cats with allergic dermatitis receiving ciclosporin. Veterinary Dermatology 2011, 22:511-520.
13. Kovalik M., Taszkun I., Pomorski Z., Kozak M., Pomorska D., Szczepanik M., Wilkolek P., Palenik L., Shaw D.J., van den Broek A.H., Thoday K.L. Evaluation of a human generic formulation of ciclosporin in the treatment of canine atopic dermatitis with in vitro assessment of the functional capacity of phagocytic cells. Veterinary Record 2011, 168:537.
14. Kovalik M., Thoday K.L., Handel I.G., Bronsvoort B.M., Evans H., van den Broek A.H., Mellanby R.J. Ciclosporin A therapy is associated with disturbances in glucose metabolism in dogs with atopic dermatitis. Veterinary Dermatology 2011, 22:173-180.
15. Mrowietz U., Ruzicka T. Cyclosporine for psoriasis. Dermatology and Therapy 1999, 11:60-66.
16. Nuttall T., Mueller R., Bensignor E., Verde M., Noli C., Schmidt V., Rème C. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: A randomised, double blind, placebo-controlled trial. Veterinary Dermatology 2009, 20:191-198.
17. Nuttall T.J., McEwan N.A., Bensignor E., Cornegliani L., Löwenstein C., Rème C.A. Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis. Veterinary Dermatology 2012, 23:4-10.
18. Olivry T., Rivierre C., Jackson H.A., Murphy K.M., Davidson G., Sousa C.A. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: A blinded randomized prednisolone-controlled trial. Veterinary Dermatology 2002, 13:77-87.
19. Olivry T., Steffan J., Fisch R.D., Prélaud P., Guaguère E., Fontaine J., Carlotti D.N. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. Journal of the American Veterinary Medical Association 2002, 221:370-377. European Veterinary Dermatology Cyclosporin Group.
20. Olivry T., DeBoer D.J., Favrot C., Jackson H.A., Mueller R.S., Nuttall T., Prélaud P., The International Task Force on Canine Atopic Dermatitis Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Veterinary Dermatology 2010, 21:233-248.
21. Olivry T., Foster A.P., Mueller R.S., McEwan N.A., Chesney C., Williams H.C. Interventions for atopic dermatitis in dogs: A systematic review of randomized controlled trials. Veterinary Dermatology 2010, 21:4-22.
22. Paul A.E., Mansfield C.S., Thompson M. Presumptive Nocardia spp. infection in a dog treated with cyclosporin and ketoconazole. New Zealand Veterinary Journal 2010, 58:265-268.
23. Radowicz S.N., Power H.T. Long-term use of cyclosporine in the treatment of canine atopic dermatitis. Veterinary Dermatology 2005, 16:81-86.
24. Ring J., Möhrenschlager M., Henkel V. The US FDA "black box" warning for topical calcineurin inhibitors: An ongoing controversy. Drug Safety 2008, 31:185-198.
25. Ryan C., Amor K.T., Menter A. The use of cyclosporine in dermatology: Part II. Journal of the American Academy of Dermatology 2010, 63:949-972.
26. Sperr W.R., Agis H., Czerwenka K., Virgolini I., Bankl H.C., Müller M.R., Zsebo K., Lechner K., Valent P. Effects of cyclosporine A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. Journal of Allergy and Clinical Immunology 1996, 98:389-399.
27. Steffan J., Alexander D., Brovedani F., Fisch R.D. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: A parallel, blinded, randomized controlled trial. Veterinary Dermatology 2003, 14:11-22.
28. Steffan J., Parks C., Seewald W. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. Journal of the American Veterinary Medical Association 2005, 226:1855-1863. North American Veterinary Dermatology Cyclosporine Study Group.
29. Steffan J., Favrot C., Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for treatment of atopic dermatitis in dogs. Veterinary Dermatology 2006, 17:3-16.
30. Stepkowski S.M. Molecular targets for existing and novel immunosuppressive drugs. Expert Reviews in Molecular Medicine 2000, 2:1-23.
31. White D.J., Plumb A.M., Pawelec G., Brons G. Cyclosporin A: An immunosuppressive agent preferentially active against proliferating T cells. Transplantation 1979, 27:55-58.
32. Willemse T. Atopic skin disease: A review and a reconsideration of diagnostic criteria. Journal of Small Animal Practice 1986, 27:771-778.
33. Won Y.H., Sauder D.N., McKenzie R.C. Cyclosporin A inhibits keratinocyte cytokine gene expression. British Journal of Pharmacology 1994, 130:312-319.